Literature DB >> 3153341

Paediatric cadaveric renal transplantation. Initial experience with a triple therapy immunosuppressive regimen.

R G Walker1, A J d'Apice, H R Powell, D M Francis, D A McCredie, P Kincaid-Smith.   

Abstract

Since June 1985 ten consecutive paediatric cadaveric renal transplant recipients (aged from 7 to 15 years) have been studied prospectively to evaluate a triple immunosuppressive regime of low-dose cyclosporin A (CyA), azathioprine (AZA) and prednisolone (PNL) with the aim of eliminating PNL from the regime within 6 months. Follow-up has been over 6-18 months. Patient and graft survival are both 100%. Median (range) serum creatinine values at 6 months were 0.09 (0.05-0.14) mmol/l (n = 10) and 0.09 (0.06-0.16) mmol/l (n = 5) at 12 months. Readily reversible acute rejection episodes occurred in five patients (50%); two of these episodes occurred soon after cessation of PNL. Six months post-transplantation, PNL had been discontinued in six patients (60%). After 12 months, three of five patients were still not receiving PNL. Complications included hypertension (seven patients), cytomegaloviral infections (three patients), labial herpes simplex (one patient), leucopenia (two patients), marked hirsutism (four patients) and transient CyA nephrotoxicity (one patient). Following transplantation, all children had growth velocities greater than 5 cm/year and seven have growth patterns which suggest that "catch-up growth" may be occurring. This preliminary study shows that a triple immunosuppressive regime of low-dose CyA, AZA and PNL allows excellent patient survival, graft survival and graft function and has been associated with few complications, including a low incidence of CyA nephrotoxicity. Growth rates are very encouraging and in a high proportion of children it has been possible to discontinue PNL completely.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3153341     DOI: 10.1007/bf00853598

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  7 in total

1.  Growth retardation in children with chronic renal disease: scope of the problem.

Authors:  G Rizzoni; M Broyer; G Guest; R Fine; M A Holliday
Journal:  Am J Kidney Dis       Date:  1986-04       Impact factor: 8.860

2.  Cyclosporin in renal transplantation in children.

Authors:  B Klare; J von Walter; H Hahn; P Emmrich; W Land
Journal:  Lancet       Date:  1984-09-22       Impact factor: 79.321

3.  The effect of long-term cyclosporin A on renal function.

Authors:  D V Hamilton; R Y Calne; D B Evans; R G Henderson; S Thiru; D J White
Journal:  Lancet       Date:  1981-05-30       Impact factor: 79.321

4.  Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.

Authors:  R Y Calne; K Rolles; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; R G Henderson; S Aziz; P Lewis
Journal:  Lancet       Date:  1979-11-17       Impact factor: 79.321

5.  Dosage of Cyclosporin A in children with renal transplants.

Authors:  P F Hoyer; G Offner; K Wonigeit; J Brodehl; R Pichlmayr
Journal:  Clin Nephrol       Date:  1984-08       Impact factor: 0.975

6.  Use of cyclosporine in pediatric renal transplant recipients.

Authors:  S B Conley; S M Flechner; G Rose; C T Van Buren; E Brewer; B D Kahan
Journal:  J Pediatr       Date:  1985-01       Impact factor: 4.406

7.  Liver and kidney transplantation in children receiving cyclosporin A and steroids.

Authors:  T E Starzl; S Iwatsuki; J J Malatack; B J Zitelli; J C Gartner; T R Hakala; J T Rosenthal; B W Shaw
Journal:  J Pediatr       Date:  1982-05       Impact factor: 4.406

  7 in total
  1 in total

1.  Triple immunosuppression with subsequent prednisolone withdrawal: 6 years' experience in paediatric renal allograft recipients.

Authors:  S M Chao; C L Jones; H R Powell; L Johnstone; D M Francis; G J Becker; R G Walker
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.